TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07298421: A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Children Aged 2-17 Years With

Sponsor: Hoffmann-La Roche · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,630,830

Rescue Site Savings

+$7,005,570

Unlock Full NCT07298421 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07298421 Rescue Dossier →